ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Gene expression signatures are crucial for cancer subtyping and predicting outcomes.
• Current kidney cancer diagnostics lack clinically applicable molecular signatures.

Purpose of the Study:

• Develop a novel gene expression biomarker for clear cell renal cell carcinoma (ccRCC) risk stratification.
• Classify ccRCC into good-risk (ccA) and poor-risk (ccB) subtypes for improved clinical management.

Main Methods:

• A 34-gene classifier (ClearCode34) was developed using ccRCC sample standards.
• The classifier was validated on RNA-sequencing data from The Cancer Genome Atlas (TCGA) and clinical formalin-fixed samples.

Main Results:

• ClearCode34 effectively classified ccRCC tumors into ccA and ccB subtypes.
• Subtype classification showed significant associations with recurrence-free survival, cancer-specific survival, and overall survival (p<0.01).
• The 34-gene signature demonstrated prognostic value comparable to tumor stage and grade.

Conclusions:

• The ClearCode34 gene signature provides robust prognostic stratification for nonmetastatic ccRCC.
• An integrated molecular and clinical model using ClearCode34 improves prediction of patient outcomes.
• This biomarker enhances risk assessment for recurrence and mortality in ccRCC patients.